YQ23
/ New Beta Innovation
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
December 08, 2023
YAN: YQ23 Study in Patients With Critical Limb Ischaemia
(clinicaltrials.gov)
- P1/2 | N=5 | Terminated | Sponsor: New Beta Innovation Limited | Phase classification: P1b/2a ➔ P1/2 | N=51 ➔ 5 | Trial completion date: Jun 2024 ➔ Aug 2023 | Active, not recruiting ➔ Terminated; Due to business decision
Enrollment change • Phase classification • Trial completion date • Trial termination • Cardiovascular • Peripheral Arterial Disease
December 08, 2023
A Safety Study of YQ23 in Advanced Solid Tumors Patients
(clinicaltrials.gov)
- P1 | N=3 | Terminated | Sponsor: New Beta Innovation Limited | N=30 ➔ 3 | Trial completion date: Dec 2024 ➔ Jul 2023 | Active, not recruiting ➔ Terminated; Due to business decision
Enrollment change • Trial completion date • Trial termination • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer
March 09, 2023
A Safety Study of YQ23 in Advanced Solid Tumors Patients
(clinicaltrials.gov)
- P1 | N=30 | Active, not recruiting | Sponsor: New Beta Innovation Limited | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Jun 2024
Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3
January 06, 2023
YAN: YQ23 Study in Patients With Critical Limb Ischaemia
(clinicaltrials.gov)
- P1b/2a | N=51 | Recruiting | Sponsor: New Beta Innovation Limited | Active, not recruiting ➔ Recruiting | Trial completion date: Sep 2023 ➔ Jun 2024 | Trial primary completion date: May 2023 ➔ Dec 2023
Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Peripheral Arterial Disease
February 09, 2022
YAN: YQ23 Study in Patients With Critical Limb Ischaemia
(clinicaltrials.gov)
- P1b/2a | N=51 | Active, not recruiting | Sponsor: New Beta Innovation Limited | Recruiting ➔ Active, not recruiting
Enrollment closed • Peripheral Arterial Disease
February 05, 2022
The anti-tumoral effects of the oxygen carrier YQ23 in a triple-negative breast cancer syngeneic model.
(PubMed, Transl Cancer Res)
- "In concordance with the weakened immunosuppression, the inflammatory cytokine interferon γ and cytolytic granzyme B were upregulated. YQ23 treatment may be a potential therapeutic strategy to modulate the TME in TNBC."
Journal • Breast Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CD8 • GZMB • IFNG • PD-1
October 08, 2021
A Safety Study of YQ23 in Advanced Solid Tumors Patients
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: New Beta Innovation Limited; Trial completion date: Dec 2022 ➔ Dec 2023; Trial primary completion date: Dec 2021 ➔ Dec 2022
Clinical • Combination therapy • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3
October 15, 2021
The Protective Effect of a Novel Cross-Linked Hemoglobin-Based Oxygen Carrier on Hypoxia Injury of Acute Mountain Sickness in Rabbits and Goats.
(PubMed, Front Physiol)
- "Besides, YQ23 exhibited no adverse effects on hemodynamics, myocardial ischemia, and renal injury. In conclusion, YQ23 effectively alleviates acute altitude hypoxia injury of AMS without aside effects."
Journal • Preclinical • Cardiovascular • Coronary Artery Disease • Hepatology • Liver Failure • Myocardial Ischemia • Renal Disease
June 29, 2021
A Safety Study of YQ23 in Advanced Solid Tumors Patients
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: New Beta Innovation Limited; Active, not recruiting ➔ Recruiting
Clinical • Combination therapy • Enrollment open • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3
June 01, 2021
A Novel Cross-Linked Hemoglobin-Based Oxygen Carrier, YQ23, Extended the Golden Hour for Uncontrolled Hemorrhagic Shock in Rats and Miniature Pigs.
(PubMed, Front Pharmacol)
- " HBOC, such as YQ23, played vital roles in damage-control resuscitation for emergency care and benefited the uncontrolled hemorrhagic shock in the pre-hospital treatment by increasing oxygen delivery, reducing organ injury. Besides, HBOC could benefit the injured and trauma patients by extending the Golden Hour."
Journal • Preclinical • Hematological Disorders • Renal Disease
April 19, 2021
YAN: YQ23 Study in Patients With Critical Limb Ischaemia
(clinicaltrials.gov)
- P1b/2a; N=51; Recruiting; Sponsor: New Beta Innovation Limited; Not yet recruiting ➔ Recruiting
Enrollment open • Peripheral Arterial Disease
March 08, 2021
A Safety Study of YQ23 in Advanced Solid Tumors Patients
(clinicaltrials.gov)
- P1; N=30; Active, not recruiting; Sponsor: New Beta Innovation Limited; Recruiting ➔ Active, not recruiting
Clinical • Combination therapy • Enrollment closed • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3
March 03, 2021
First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23
(clinicaltrials.gov)
- P1; N=58; Completed; Sponsor: New Beta Innovation Limited; Active, not recruiting ➔ Completed
Clinical • Trial completion
October 19, 2020
First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23
(clinicaltrials.gov)
- P1; N=58; Active, not recruiting; Sponsor: New Beta Innovation Limited; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
September 14, 2020
A Safety Study of YQ23 in Advanced Solid Tumors Patients
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: New Beta Innovation Limited; Not yet recruiting ➔ Recruiting
Clinical • Combination therapy • Enrollment open • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • TNNI3
August 14, 2020
A Safety Study of YQ23 in Advanced Solid Tumors Patients
(clinicaltrials.gov)
- P1; N=30; Not yet recruiting; Sponsor: New Beta Innovation Limited
Clinical • Combination therapy • New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer
1 to 16
Of
16
Go to page
1